Have a feature idea you'd love to see implemented?
Let us know!
FENC Fennec Pharmaceuticals Inc
Price (delayed)
$4.58
Market cap
$125.33M
P/E Ratio
45.8
Dividend/share
N/A
EPS
$0.1
Enterprise value
$112.04M
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation
Highlights
The company's EPS has surged by 110% YoY and by 11% QoQ
The quick ratio has soared by 55% YoY and by 14% from the previous quarter
The equity has plunged by 145% from the previous quarter but it has soared by 86% YoY
Fennec Pharmaceuticals's net income has soared by 114% YoY but it has decreased by 2.9% from the previous quarter
FENC's debt is up by 21% year-on-year
Key stats
What are the main financial stats of FENC
Market
Valuations
Earnings
Shares outstanding
27.36M
Market cap
$125.33M
Enterprise value
$112.04M
Price to earnings (P/E)
45.8
Price to book (P/B)
N/A
Price to sales (P/S)
2.56
EV/EBIT
14.96
EV/EBITDA
13.6
EV/Sales
2.29
Revenue
$48.89M
EBIT
$7.49M
EBITDA
$8.24M
Free cash flow
$23.04M
Per share
Balance sheet
Liquidity
EPS
$0.1
Free cash flow per share
$0.84
Book value per share
-$0.05
Revenue per share
$1.79
TBVPS
$2.31
Total assets
$63.16M
Total liabilities
$64.52M
Debt
$29.77M
Equity
-$1.36M
Working capital
$54.42M
Debt to equity
-21.93
Current ratio
8.02
Quick ratio
7.14
Net debt/EBITDA
-1.61
Margins
Efficiency
Dividend
EBITDA margin
16.9%
Gross margin
95.6%
Net margin
7.4%
Operating margin
12%
Return on assets
8.2%
Return on equity
N/A
Return on invested capital
20.9%
Return on capital employed
13.5%
Return on sales
15.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FENC stock price
How has the Fennec Pharmaceuticals stock price performed over time
Intraday
2.69%
1 week
-1.51%
1 month
-7.29%
1 year
-33.82%
YTD
-59.18%
QTD
-8.4%
Financial performance
How have Fennec Pharmaceuticals's revenue and profit performed over time
Revenue
$48.89M
Gross profit
$46.72M
Operating income
$5.87M
Net income
$3.64M
Gross margin
95.6%
Net margin
7.4%
The operating income has soared by 124% YoY but it fell by 6% QoQ
Fennec Pharmaceuticals's net income has soared by 114% YoY but it has decreased by 2.9% from the previous quarter
Fennec Pharmaceuticals's operating margin has soared by 103% YoY but it has decreased by 14% from the previous quarter
FENC's net margin has surged by 102% year-on-year but it is down by 11% since the previous quarter
Growth
What is Fennec Pharmaceuticals's growth rate over time
Valuation
What is Fennec Pharmaceuticals stock price valuation
P/E
45.8
P/B
N/A
P/S
2.56
EV/EBIT
14.96
EV/EBITDA
13.6
EV/Sales
2.29
The company's EPS has surged by 110% YoY and by 11% QoQ
The equity has plunged by 145% from the previous quarter but it has soared by 86% YoY
The P/S is 74% lower than the last 4 quarters average of 9.9
FENC's revenue is up by 9% from the previous quarter
Efficiency
How efficient is Fennec Pharmaceuticals business performance
The return on invested capital has surged by 124% year-on-year but it has declined by 10% since the previous quarter
The return on assets has surged by 108% year-on-year but it has declined by 27% since the previous quarter
The company's return on sales has surged by 104% YoY but it fell by 7% QoQ
Dividends
What is FENC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FENC.
Financial health
How did Fennec Pharmaceuticals financials performed over time
The total assets is 2.1% less than the total liabilities
Fennec Pharmaceuticals's total liabilities has soared by 121% YoY but it has decreased by 2.5% from the previous quarter
FENC's current ratio has soared by 57% year-on-year and by 16% since the previous quarter
The equity has plunged by 145% from the previous quarter but it has soared by 86% YoY
FENC's debt is up by 21% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.